Literature DB >> 6434631

Stimulation of immunoglobulin secretion in human B lymphocytes as a direct effect of high concentrations of IL 2.

P Ralph, G Jeong, K Welte, R Mertelsmann, H Rabin, L E Henderson, L M Souza, T C Boone, R J Robb.   

Abstract

In certain human IgM and IgG cell lines, immunoglobulin (Ig) secretion is highly stimulated by a B cell inducing factor (BIF) that is free of interleukin 2 (IL 2). BIF also induces Ig secretion in purified peripheral blood B cell populations that have been mitogenically stimulated by Staphylococcus aureus bacteria. Low concentrations of IL 2 (less than 20 U/ml) are not active in these systems. We now show that IL 2 at concentrations above 100 U/ml can induce Ig secretion in these blood B cells and B cell lines. Both conventional IL 2, purified from the human JURKAT and gibbon MLA-144 cell lines, and recombinant IL 2 are active. Very high concentrations approaching 10(4) U/ml are optimal for Ig secretion. Antibody to the T cell IL 2 receptor, anti-Tac, did not inhibit stimulation of the IgM cell line SKW6.4 by IL 2, and no Tac antigen was detected on the cells. The 9B11 monoclonal anti-IL 2 antibody that neutralizes T cell growth activity also abrogates stimulation of Ig secretion by conventional and recombinant IL 2 in the SKW6.4 cell line. However, the 1H11 monoclonal anti-(conventional thr3-glycosylated IL 2), which does not neutralize T cell growth activity, does inhibit induction of Ig secretion by the corresponding IL 2 in the B cell line. These results suggest that IL 2 stimulates B cells via a low-affinity interaction with a receptor different from the Tac receptor identified on T cells, and that the active site on the IL 2 molecule for B cells differs from that for T cell targets. If IL 2 promotes Ig secretion by binding with a low affinity to the B cell BIF receptor, IL 2 and BIF could be homologous proteins.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6434631

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Recombinant interleukin 2 and gamma-interferon act synergistically on distinct steps of in vitro terminal human B cell maturation.

Authors:  A S Fauci
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

2.  Helper activity by human large granular lymphocytes in in vitro immunoglobulin synthesis.

Authors:  M A Rodriguez; I Blanca; M L Baroja; S Arama; M Leon-Ponte; I Abadi; N E Bianco
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

3.  Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2.

Authors:  S Yamaguchi; M Onji; H Kondoh; H Miyaoka; Y Ohta
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

4.  Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors.

Authors:  R J Robb; C M Rusk; J Yodoi; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

5.  Role of aryl hydrocarbon receptor polymorphisms on TCDD-mediated CYP1B1 induction and IgM suppression by human B cells.

Authors:  Natalia Kovalova; Maria Manzan; Robert Crawford; Norbert Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  2016-08-14       Impact factor: 4.219

6.  IL-2 infusion abrogates humoral immune responses in humans.

Authors:  D J Gottlieb; H G Prentice; H E Heslop; C Bello; M K Brenner
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

Review 7.  Administration of recombinant IL-2 augments the level of serum IgM in an IL-2 deficient patient.

Authors:  S Doi; O Saiki; T Hara; T Sugita; K Ha-Kawa; T Tanaka; H Hara; S Negoro; H Yabuuchi; S Kishimoto
Journal:  Eur J Pediatr       Date:  1989-06       Impact factor: 3.183

8.  Role of interferon-gamma on the in vivo expression of functional interleukin-2 receptors by murine macrophages.

Authors:  B Dugas; L Friteau; H Schellekens; D Lando; C Damais
Journal:  Inflammation       Date:  1991-06       Impact factor: 4.092

9.  Development of plasmacytoid cells with Russell bodies in autoimmune "viable motheaten" mice.

Authors:  L D Shultz; D R Coman; B L Lyons; C L Sidman; S Taylor
Journal:  Am J Pathol       Date:  1987-04       Impact factor: 4.307

Review 10.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.